Scholars Central

Short communicationPublished 30 Sep 2020

Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction

Authors: Shixiang Wang

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Immunotherapy, represented by immune checkpoint inhibitors (ICI), is transforming the treatment of cancer. However, only a small percentage of patients show response to ICI and there is an unmet need for biomarkers that will identify patients who are more likely to respond to immunotherapy. The fundamental basis for ICI response is the immunogenicity of a tumor, which is primarily determined by tumor antigenicity and antigen presentation efficiency. Here, we propose a method to measure tumor immunogenicity score (TIGS), which combines tumor mutational burden (TMB) and an expression signature of the antigen processing and presenting machinery (APM). In both correlation with pan-cancer ICI objective response rates (ORR) and ICI clinical response prediction for individual patients, TIGS consistently showed improved performance compared to TMB and other known prediction biomarkers for ICI response. This study suggests that TIGS is an effective tumor inherent biomarker for ICI-response prediction.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Stem Cell Research and Regenerative Medicine.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalStem Cell Research and Regenerative Medicine
  • SubjectGenetics & Molecular Biology
  • BylineArticles whose byline prints “Shixiang Wang”